Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON L8S4L8, Canada.
Department of Medicine, Imperial College Healthcare NHS Trust, Fulham Palace Road, London, UK, W68RF.
J Subst Use Addict Treat. 2024 Feb;157:209210. doi: 10.1016/j.josat.2023.209210. Epub 2023 Nov 4.
Inpatient addiction medicine services (AMS) were developed in response to the growing needs of hospitalized individuals with substance use disorders (SUDs). AMS aim to enable timely initiation of pharmacologic treatment, build hospital capacity to support patients who use substances, and facilitate transition to community services. As an emerging service being adopted in hospitals across North America, the model of care, populations served, substance use trends, and clinical trajectory has not been widely described. This work aims to characterize patients accessing care through the AMS, establishing predictors for clinical trajectories in hospital including patient-initiated discharge (PID) and hospital re-admission.
Using a retrospective cohort design, we describe all patients seen by the AMS between 2018 and 2022 across four hospitals in Hamilton, Ontario. Patients seen by AMS were hospitalized and qualified for a SUD based on DSM-V criteria. The study used descriptive statistics to describe the cohort, where appropriate adjusted time-to-event survival models were constructed to identify predictors for hospital re-admission.
Patients seen by the AMS (n = 695) frequently lacked access to primary care (47.0 %) and less than half (44.3 %) were receiving community addiction services on admission. The majority met criteria for opioid use disorder (OUD), with injecting being the primary consumption route (54.8 %). Patients exhibited high acuity, with 34.2 % requiring critical care measures. Provision of OAT substantially increased to 77.9 % of patients (29 % on admission). PID occurred in 17.8 % of patients and was significantly associated with an admitting diagnosis of suicidal ideation, infection, heart failure, and distinct substance use profiles including methamphetamine, fentanyl, and heroin use (p < 0.05). PID conferred a 66 % increased risk for re-admission (Hazard-Ratio: 1.66; 95 % CI: 1.08, 2.54; p = 0.02).
Patients served by AMS primarily include individuals with OUD presenting with the associated medical complications and substantial deficits in the social determinants of health (e.g., high housing insecurity, poverty, and disability). PID occurs among 1 in 5 people and is associated with higher rates of re-admission. By identifying individuals at higher risk of adverse outcomes, these results provide an opportunity to improve outcomes in this high-risk, high-vulnerability population.
住院成瘾医学服务(AMS)是为满足住院患者物质使用障碍(SUD)日益增长的需求而开发的。AMS 的目的是使药物治疗能够及时开始,增强医院支持使用物质的患者的能力,并促进向社区服务的过渡。作为一种在北美各地医院采用的新兴服务模式,其护理模式、服务人群、物质使用趋势和临床轨迹尚未得到广泛描述。这项工作旨在描述通过 AMS 获得治疗的患者,确定包括患者发起出院(PID)和医院再入院在内的住院临床轨迹的预测因素。
我们使用回顾性队列设计,描述了 2018 年至 2022 年期间安大略省汉密尔顿的四家医院 AMS 治疗的所有患者。通过 AMS 就诊的患者因 DSM-V 标准住院并符合 SUD 条件。该研究使用描述性统计来描述队列,适当时构建调整后的时间事件生存模型,以确定再入院的预测因素。
通过 AMS 就诊的患者(n=695)经常无法获得初级保健(47.0%),不到一半(44.3%)在入院时正在接受社区成瘾服务。大多数患者符合阿片类药物使用障碍(OUD)的标准,主要的消费途径是注射(54.8%)。患者表现出高度的严重性,有 34.2%需要重症监护措施。为患者提供 OAT 的比例大幅增加至 77.9%(入院时 29%)。17.8%的患者发生 PID,与自杀意念、感染、心力衰竭的入院诊断以及包括冰毒、芬太尼和海洛因在内的不同物质使用模式显著相关(p<0.05)。PID 使再入院的风险增加了 66%(风险比:1.66;95%CI:1.08,2.54;p=0.02)。
AMS 服务的主要人群包括阿片类药物使用障碍患者,他们伴有相关的医疗并发症以及健康社会决定因素的严重不足(例如,住房不安全、贫困和残疾)。1/5 的患者发生 PID,且再入院率较高。通过识别有更高不良后果风险的个体,这些结果为改善这一高风险、高脆弱性人群的结局提供了机会。